Continuing Education Activity
Unconjugated hyperbilirubinemia is a condition defined as elevated serum or plasma bilirubin (unconjugated) levels above the reference range of the laboratory. Unconjugated hyperbilirubinemia usually results from dysregulation in the bilirubin metabolism that includes increased production, impaired hepatic uptake, and decreased conjugation of bilirubin. In newborns, unconjugated hyperbilirubinemia is very common, and increased bilirubin (UCB) levels can cause life-threatening kernicterus. This activity describes the pathophysiology and management of unconjugated hyperbilirubinemia. It also highlights the importance of teamwork in the management of patients with this disease.
- Describe the physiology of bilirubin metabolism.
- Explain how to differentiate unconjugated hyperbilirubinemia from conjugated hyperbilirubinemia.
- Identify the severe causes of unconjugated hyperbilirubinemia and summarizes the available treatment options.
- Summarize the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by unconjugated hyperbilirubinemia.
Hyperbilirubinemia is a condition defined as elevated serum or plasma bilirubin levels above the reference range of the laboratory, and it is due to disorders of bilirubin metabolism. Depending on the form of bilirubin present in serum, hyperbilirubinemia can be further classified as unconjugated (indirect) or conjugated (direct). Unconjugated hyperbilirubinemia (albumin-bound) usually results from increased production, impaired hepatic uptake, and decreased conjugation of bilirubin. In neonates, jaundice typically occurs due to unconjugated hyperbilirubinemia, which is characterized by the increased levels of indirect or unconjugated bilirubin (UCB) in the serum. In newborns, the increased concentration of UCB can cross the blood-brain barrier, and deposit in the basal ganglia or cerebellum causes a bilirubin-induced encephalopathy or kernicterus. Several inherited disorders can also produce unconjugated hyperbilirubinemia, including Gilbert syndrome, Crigler-Najjar syndromes type I and II, and inherited disorders causing hemolytic anemia.
Bilirubin, a yellow-orange bile pigment, is the catabolic product of heme metabolism. Approximately 85 percent of the heme moiety comes from the hemoglobin degradation of red blood cells, while the remaining derives from the ineffective erythropoiesis and the breakdown of other hemoproteins such as cytochromes, myoglobin, and catalase. The conversion of heme to bilirubin is a two-step reaction, in the first step the microsomal heme oxygenase enzyme of the reticuloendothelial system, converts heme to biliverdin, which in turn is reduced to unconjugated bilirubin (UCB) by a second enzyme biliverdin reductase. The UCB is lipophilic. UCB tightly bound to albumin is transported to the liver. The entry of UCB into the liver has not been elucidated, and the best candidate appears to be a bilirubin transporter. In liver hepatocytes, UCB dissociates from albumin and binds to proteins of the glutathione-S-transferases family that present it for conjugation and prevent it effluxing from the liver. Next, unconjugated bilirubin gets conjugated with one or two molecules of glucuronic acid by the enzyme UDP-glucuronosyltransferase (UGT1A1), which forms bilirubin monoglucuronide and bilirubin diglucuronide respectively. Conjugation increases the solubility of bilirubin in plasma and thereby enhances its elimination from the body. The CB then pumped into bile via an energy-requiring process requiring the multidrug resistance-associated protein 2 (MRP2). This process also reduces the ability of bilirubin to diffuse across the blood-brain barrier. Therefore, unconjugated hyperbilirubinemia can result from dysfunction of any of these conjugation steps. In neonates, inefficient conjugation of bilirubin leads to unconjugated hyperbilirubinemia (physiologic neonatal jaundice).
Unconjugated hyperbilirubinemia arises in one of the three major pathophysiologic conditions or a combination of them:
- Increased bilirubin production
- Impaired bilirubin uptake
- Impaired bilirubin conjugation
Increased bilirubin production and consequential unconjugated hyperbilirubinemia can result from increased catabolic degradation of hemoglobin and other heme proteins, typically due to accelerated hemolysis, a large hematoma, dyserythropoiesis (e.g., megaloblastic and sideroblastic anemias) or sometimes due to destruction of transfused erythrocytes. In these conditions, patients with normal liver function efficiently conjugate and excrete the excess bilirubin. As a result, the serum levels of unconjugated bilirubin remain modest (1 to 4 mg/dL) and rarely exceeds 4 mg/dL. Prolonged hemolysis can lead to severe hyperbilirubinemia in patients with concurrent hepatic dysfunction.
The impaired hepatic uptake of bilirubin can be the result of decreased bilirubin delivery to the liver and inefficient uptake of bilirubin by hepatocytes, usually resulting from reduced hepatic blood flow (congestive heart failure and portosystemic shunts) and drugs/contrast administration. The unconjugated hyperbilirubinemia induced by several drugs (rifampin, flavaspidic acid, novobiocin, and various cholecystographic contrast agents), generally resolves within 48 hours of drug discontinuation.
Impaired bilirubin conjugation can result from hereditary defects, including Gilbert syndrome and the Crigler-Najjar syndrome type I and II, that cause a decrease or loss of UDP-glucuronosyltransferase (UGT1A1) activity, an enzyme responsible for conjugation of bilirubin with glucuronic acid. Lucy-Driscoll syndrome, also known as Maternal serum jaundice, a form of transient familial neonatal unconjugated hyperbilirubinemia, is a rare metabolic disorder caused by a UGT1A1 inhibitor usually present in the maternal serum. Most of the newborn develops unconjugated hyperbilirubinemia (neonatal jaundice) because of hepatic immaturity and low activity of UGT1A1 during days 2 to 5. Breast milk feeding increases bilirubin levels in infants that result in maternal milk jaundice. Drugs such as novobiocin, pregnanediol, chloramphenicol, gentamycin, and several HIV protease inhibitors can induce hyperbilirubinemia by inhibiting UGT1A1 enzyme. In newborn, ABO/Rh incompatibility may lead to hyperbilirubinemia and consequently, neonatal jaundice.
Approximately 50% of full-term and 80% of preterm infants develop jaundice in the first 2 to 4 days after birth when serum bilirubin levels around 5mg/dL. Crigler-Najjar syndrome is a very rare disease with less than fifty cases in the United States and approximately 1 case per million births worldwide. In the United States, the prevalence of Gilbert syndrome is relatively higher; around 9% of the population is homozygous for UGT1A1 mutation. In Gilbert syndrome, ethnic groups specific mutations occur at a different site of the UGT1A1 gene. For example, Gilbert syndrome in the white population commonly associates with the mutation in the TATAA element of the UGT1A1 promoter region. Neonatal jaundice is common in male infants, while Crigler-Najjar syndrome does not correlate with sex. At the stage of puberty, Gilbert syndrome is more common in male than a female that can be due to the high rate of bilirubin production in male than female. In 0.5 to 2.4% of infants, breast milk jaundice occurs between days 2 and 5 after birth due to increased enterohepatic circulation of bilirubin.
Jaundice is evident when the serum bilirubin level exceeds 3mg/dL. Gilbert syndrome and Crigler-Najjar syndrome type I and II, are hereditary non-hemolytic unconjugated hyperbilirubinemias that result from the mutations in UGT1A1 gene and impairs bilirubin conjugation. In Gilbert syndrome, UGT1A1 enzyme activity is 10 to 30% of normal, which results in mild unconjugated hyperbilirubinemia with bilirubin levels below 5 mg/dL. The decreased activity of UGT1A1 results from the addition of extra thymine-adenine (TA) repeats in the TATAA box region of the UGT1A1 gene promoter. Individuals with Gilbert syndrome have a relatively benign course. Crigler-Najjar types I and II syndromes are inherited autosomal recessive disorder results from the mutations in any one or more of the five exons of the gene that encodes the UGT1A1 enzyme. In Crigler-Najjar type I (CNS1), UGT1A1 enzyme activity is absent, leading to a severe increase in unconjugated bilirubin levels ranging from 20 to 45 mg/dL. In the neonatal period, infants with Crigler-Najjar type I syndrome usually develop bilirubin encephalopathy (Kernicterus) with seizures, opisthotonos, and dies with severe neurologic diseases in the absence of treatment.
Individuals with Crigler-Najjar type II (CNS2) have less than 10% of the normal UGT1A1 activity, resulting in bilirubin levels of 5 to 25 mg/dL. Kernicterus is rare in Crigler-Najjar type II, but patients with increased bilirubin levels (greater than 15 mg/dL) have high chances of its occurrence. Kernicterus can occur under stress and with inter-current illnesses. Also, CNS2 therapy with phenobarbital can lower the UCB levels by 25%.
History and Physical
Patients with unconjugated hyperbilirubinemia may present with jaundice or other signs, or the condition may be noticed in the asymptomatic patient by the finding of high levels of bilirubin in the serum during a routine blood testing. The differential diagnosis of unconjugated hyperbilirubinemia is involved, which requires a detailed history and physical examination of patients for the evaluation. The assessment of the patient’s clinical history includes; age at the disease manifestation, ethnic origin/race, hereditary disorder, family history of anemia or jaundice, recently used medications, diet history, and history of liver disease.
Approximately 50% of neonates present with physiologic jaundice during the first five days after birth. Nonphysiologic, Lucey-Driscoll syndrome, or maternal serum jaundice in neonates results from maternal serum during the initial four days after delivery. The onset of asymptomatic jaundice usually characterizes the overproduction of bilirubin due to ineffective erythropoiesis (ELB production). Patients with Gilbert syndrome are generally asymptomatic and present with mild or intermittent unconjugated hyperbilirubinemia without any liver disease or hemolysis, and on clinical examination may manifest jaundice. Some nonspecific symptoms, such as fatigue, abdominal cramps, and malaise, are commonly observed in this disease. Infants with Crigler-Najjar type I syndrome present jaundice in the first few days after birth with neurological sequelae if UCB is greater than 20 mg/dL. By the second week of an infant’s life, it rapidly progresses to life-threatening severe jaundice that requires treatment with exchange transfusion, intensive phototherapy, and liver transplantation. However, patients with Crigler-Najjar type II syndrome, are mostly asymptomatic and may rarely present with jaundice and kernicterus. During the physical examination, the color of the skin and sclerae should be examined carefully under light for the evaluation of jaundice. For example, in patients with mild jaundice or hyperbilirubinemia (2 to 3 mg/dL), only scleral icterus can be seen. Also, with hemolytic anemia, there might be anemia and splenomegaly.
The initial assessment of the patient presenting with jaundice depends on whether hyperbilirubinemia is the result of unconjugated or conjugated bilirubin. A urine test positive for bilirubin indicates conjugated hyperbilirubinemia. Conjugated bilirubin is soluble in water; therefore, it can be excreted via urine but not unconjugated due to water insolubility. Further, first-line laboratory testing should include measurement of the serum total bilirubin levels with fractionation (direct with indirect obtained by subtraction from total), followed by serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase and γ-glutamyl transpeptidase (GGT) levels, complete blood count (CBC) with examination of smear, a reticulocyte count, and a direct Coombs test , Lactate dehydrogenase (LDH) and haptoglobin levels. Jaundice, with a toxic appearance, fever, or abnormal count of white blood cells indicates sepsis that requires prompt evaluation and adequate treatment. The increased levels of AST and ALT are markers of the hepatocyte damage/injury. However, increased levels of alkaline phosphatase and γ-glutamyltransferase suggest cholestasis.
A complete blood count is a beneficial test for the determination of hemolysis, which is characterized by the presence of damaged red blood cells and increased reticulocytes on the smear. In patients, when the serum total bilirubin levels exceed 3.0 mg/dL, jaundice becomes clinically apparent. The hyperbilirubinemia is unconjugated when the conjugated bilirubin level is less than 15% of the TB. While in conjugated hyperbilirubinemia, conjugated bilirubin level is high and more than 20% of the total bilirubin. Generally, patients with carotenemia also present yellow skin but have no elevation in serum bilirubin levels. During the physical examination, carotenemia due to excess carotene intake, e.g., carrots, peaches, etc., can be distinguished from jaundice due to the absence of scleral icterus in carotenemia with the pigmentation of soles and palms and other areas. Computerized axial tomography (CT) and ultrasonography scanning are useful tools in diagnosing cholestasis (intra-hepatic and extra-hepatic) from hepatocellular disease in the assessment of a patient with conjugated hyperbilirubinemia which is not the focus of the review.
Treatment / Management
In most cases of mild neonatal jaundice, no treatment is necessary, and it resolves on its own within a few weeks. In cases of moderate or severe jaundice (TB over 15 mg/dL), phototherapy is a safe option. During phototherapy, the infant’s skin is exposed to light in the blue-green spectrum in a way that transforms bilirubin in a water-soluble isomer and reduces its toxicity by increasing its elimination in both the urine and stool. It is crucial to maintain proper hydration and urine output during phototherapy.
In some cases, infants carry antibodies from the mother that can result in the quick breakdown of neonatal red blood cells (due to difference in the blood type), intravenous transfusion of an immunoglobulin (IVIG) that can reduce the levels of antibodies may be the choice of treatment. In a rare instance of severe neonatal jaundice, when other treatments do not work, exchange transfusion of blood may be performed. In this procedure, a small amount of infant’s blood repeatedly gets withdrawn and replaced with donor blood to dilute the levels of bilirubin and maternal antibodies.
The most crucial part for clinicians in the management and care of patients with Gilbert syndrome (GS) is to recognize that it is relatively benign with a good prognosis. The diagnosis of GS requires normal liver function tests, elevated bilirubin levels, and genetic testing to confirm the disorder further. Owing to the benign and inconsequential nature of this syndrome, the use of medications is not justified for its treatment. There exists an increased risk of side effects and toxicity from the use of certain drugs such as acetaminophen and irinotecan that are conjugated in by the liver. Phenobarbital has shown to normalize bilirubin levels.
Crigler-Najjar Type II Syndrome
Patients with Crigler-Najjar syndrome type II responds to phenobarbital therapy. Since CNS2 is milder, phenobarbital is effective in reducing plasma bilirubin levels in these patients by 25 %. In some cases, patients with severe hyperbilirubinemia may need phototherapy or exchange transfusions. However, often, patients affected with type II syndrome may not require any therapy but may need routine monitoring. The goal is to maintain TSB below 15 mg/dL.
Crigler-Najjar Type I Syndrome
Unlike CNS2, patients with CNS1 does not respond to phenobarbital therapy due to the absence of the enzyme. Rapid treatment of kernicterus is needed to prevent devastating neurologic sequelae. The emergent treatment for bilirubin encephalopathy relies on repeated plasma exchange transfusions followed by long-term phototherapy. The process of plasma exchange transfusion flushes out bilirubin-saturated albumin and provides free protein, which lures bilirubin from the tissues. To maintain the levels of unconjugated hyperbilirubinemia below the neurotoxic threshold patients with Crigler-Najjar syndrome type I generally need phototherapy for 10 to 12 hours a day. Phototherapy helps in converting bilirubin to more water-soluble bilirubin isoforms that can get excreted in the urine. The efficacy of phototherapy is dose-dependent and depends on the intensity of light, exposure of the body surface, or reflecting mirrors used. Some side effects associated with long term phototherapy are restriction of activity, delay in normal development, diarrhea, reduced weight gain, and problems in maintaining body temperature.
Oral calcium phosphate may be valuable adjuvant to phototherapy in Crigler-Najjar type I syndrome. Treatment with inhibitors of heme oxygenase (tin-mesoporphyrin) helps decrease plasma bilirubin levels but is not recommended for the long term owing to their side effects.
Plasmapheresis is also being employed to lower bilirubin levels in the blood rapidly. In this procedure, unwanted substances (toxins and plasma components) get removed from the blood, and plasma gets replaced with other human plasma before transfusing the blood back into the patient.
In patients with Crigler-Najjar syndrome type I, orthotopic liver transplantation may be considered a definite form of therapy and should be performed before the onset of neurologic damage. Gene therapy is another approach for the treatment of CNS1. Significant improvement leading to the life-long cure of the disease can be achieved clinically with gene therapy by replacing a defective gene with a normal one. Presently gene transfer that can reduce the bilirubin levels for several years by partially replacing the gene controlling bilirubin glucuronosyltransferase activity in the patients is being considered for treatment in CNS1. Long-term monitoring is important for patients at risk for a sudden increase in serum bilirubin levels.
Patients with Crigler-Najjar type II syndrome do not require any treatment and can have management with phenobarbital. Also, for Gilbert syndrome, no medical therapy is needed, and phenobarbital has been effectively shown to decrease bilirubin production. The common medications used for the treatment of patients with Crigler-Najjar type I syndrome are phenobarbital, calcium (infusions), ursodeoxycholic acid, metalloporphyrins, chlorpromazine, cholestyramine.
Phenobarbital increases both the conjugation and excretion of bilirubin by stimulating the gene for the UGT1A1 enzyme that induces the production of conjugated bilirubin and thereby reduces serum bilirubin levels by 25%.
Metalloporphyrins like tin-mesoporphyrin (SnMp) inhibit the activity of heme oxygenase enzyme, which is a rate-limiting step in the production of bilirubin from heme metabolism. Calcium (infusions) like calcium phosphate bind to bilirubin in the gut and increases bilirubin’s fecal excretion.
Unconjugated hyperbilirubinemia can be caused by dysregulation in bilirubin metabolism that includes bilirubin production, uptake in hepatocytes, and conjugation. The clinician should distinguish unconjugated hyperbilirubinemia from other conditions with similar clinical manifestations. Hemolytic anemias and resorption of hematoma significantly increase the levels of unconjugated bilirubin. Hemolytic anemias may lead to a mild increase in bilirubin levels with or without clinical symptoms. Hemolytic disorders such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, sickle cell anemia, thalassemia, and autoimmune disorder should be a consideration during diagnosis.
Inherited disorders of the enzyme glucuronosyltransferase (UGT1A1) such as Gilbert syndrome and Crigler-Najjar syndromes (CNS1 and CNS2), may impede the complete conjugation of bilirubin and thereby causes varying degrees of unconjugated hyperbilirubinemia, depending on inhibition of enzyme with each disease. In addition to inherited disorders, other conditions such as portosystemic shunts, congestive heart failure, liver damage, dyserythropoiesis, and hyperthyroidism can also contribute to impaired bilirubin conjugation and should merit consideration during diagnosis. Additional considerations in the diagnosis of unconjugated hyperbilirubinemia include drug side effects (rifampicin, probenecid, or other antibiotics), chronic liver diseases, thyrotoxicosis, infections, and physiologic neonatal jaundice results from the immature conjugating ability of UGT1A1 enzyme.
The prognosis in neonatal jaundice is excellent if the patient receives the recommended standard of care. In most of the cases, jaundice gets better within one or two weeks. In some cases, such as breast milk jaundice and maternal serum jaundice, jaundice can persist several weeks. Thus, the patient’s serum bilirubin levels need to be monitored closely, with adequate adjustments in treatment made accordingly to prevent persistent hyperbilirubinemia and thereby its consequence, kernicterus. The prognosis of patients with ineffective erythropoiesis, which causes the overproduction of bilirubin is also excellent and depends on the cause. Patients with Crigler Najjar syndrome type I have a high risk of kernicterus, and thereby presents poor prognosis and need intensive, aggressive management. However, the prognosis of Crigler Najjar syndrome type II patients is more favorable and rarely associated with kernicterus. Gilbert syndrome is a benign condition, and patients with this syndrome have an excellent prognosis. An individual affected with this inherited disorder can live a normal life. Recent studies have shown that a person with Gilbert syndrome has a low risk of cardiovascular diseases, possibly due to an increase in bilirubin ameliorating oxidative stress.
Extreme hyperbilirubinemia (TB of 25 to 30 mg/dL) can cause bilirubin encephalopathy, Kernicterus, which is usually characterized by the deposition of unconjugated bilirubin (yellow stain) in brain cells. Neuronal necrosis/damage occurs in the basal ganglia, hippocampus, hypothalamic nuclei as a bilirubin-phosphatidylcholine precipitate, diencephalon, midbrain, neuro-humoral and electrolyte control, brainstem nuclei for oculomotor and auditory function, and in the cerebellum. Clinical manifestations include cerebral palsy, deafness, seizures, etc.
Deterrence and Patient Education
Patients and their families should receive education regarding jaundice and its consequences. Patients need to understand the role of unconjugated hyperbilirubinemia in the manifestation of jaundice and its severity. Patients require counsel regarding the physical appearance or symptoms of jaundice. In the case of neonatal jaundice, parents will need to know about the cause of physiologic or non-physiologic jaundice and the treatment options available for it. Patients with any change in mental or neural behavior should immediately consult with a physician. Future parents with a family history of inherited Crigler-Najjar syndromes should seek genetic counseling.
Enhancing Healthcare Team Outcomes
The treatment of unconjugated hyperbilirubinemia requires interprofessional teamwork, as it can result from multiple disorders or diseases. As the differential diagnosis of unconjugated hyperbilirubinemia is involved, it necessitates good coordination between primary care physicians, gastroenterologists, hematologists, a pediatrician, and other specialists. The detailed history of patient medications that causes liver dysfunction is critical for the treatment. The outcome of most patients with unconjugated hyperbilirubinemia is excellent when they receive the treatment according to the accepted guidelines, except Crigler Najjar syndromes, especially Type1, which has a high risk of the life-threating kernicterus that requires lifelong monitoring and treatment.